Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. INMD
INMD logo

INMD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Inmode Ltd (INMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
13.140
1 Day change
-0.98%
52 Week Range
19.090
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

InMode Ltd (INMD) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators suggest a bearish trend, options data reflects mixed sentiment, and the company's recent financial performance shows declining profitability. While there are no significant positive catalysts or news, the stock's current price does not present a compelling entry point for long-term investment.

Technical Analysis

The technical indicators are bearish. The MACD histogram is negative and contracting (-0.117), RSI is neutral at 23.198, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its S1 support level of 13.418, with resistance levels at 14.17 and 14.923. The stock trend analysis suggests a 60% chance of further declines in the short term (-2.72% next day, -2.03% next week, -1.21% next month).

Options Data

Neutral
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The open interest put-call ratio of 0.98 indicates a balanced sentiment, while the option volume put-call ratio of 1.68 suggests bearish short-term sentiment. Implied volatility (IV) is at 36.51, with a low IV rank of 11.05, indicating limited potential for significant price swings.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
4

Positive Catalysts

  • NULL identified. There are no recent news events, significant insider or hedge fund activity, or congress trading data to suggest positive momentum.

Neutral/Negative Catalysts

  • The company's financial performance in Q4 2025 shows a significant decline in profitability, with net income down 67.35% YoY and EPS down 62.83% YoY. Gross margin also dropped slightly by 1.34%. Analysts have mixed ratings, with price targets ranging from $15 to $17, reflecting limited upside potential.

Financial Performance

In Q4 2025, revenue increased by 6.13% YoY to $103.85M, but net income dropped significantly by 67.35% YoY to $27.03M. EPS fell 62.83% YoY to 0.42, and gross margin decreased slightly to 78.28% (-1.34% YoY). The company's profitability metrics are under pressure, which is a concern for long-term investors.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have mixed ratings. Baird raised the price target to $17 from $16 with a Neutral rating, while Canaccord lowered the target to $15 from $16 with a Hold rating. Analysts highlight potential sector-wide benefits from AI and M&A activity but remain cautious on the stock.

Wall Street analysts forecast INMD stock price to rise
5 Analyst Rating
Wall Street analysts forecast INMD stock price to rise
1 Buy
4 Hold
0 Sell
Hold
Current: 13.270
sliders
Low
15
Averages
17.33
High
21
Current: 13.270
sliders
Low
15
Averages
17.33
High
21
Baird
Jeff Johnson
Neutral
maintain
$16 -> $17
AI Analysis
2026-02-11
Reason
Baird
Jeff Johnson
Price Target
$16 -> $17
AI Analysis
2026-02-11
maintain
Neutral
Reason
Baird analyst Jeff Johnson raised the firm's price target on InMode to $17 from $16 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results.
Canaccord
Hold
downgrade
$16 -> $15
2025-12-17
Reason
Canaccord
Price Target
$16 -> $15
2025-12-17
downgrade
Hold
Reason
Canaccord lowered the firm's price target on InMode to $15 from $16 and keeps a Hold rating on the shares. The firm said they are bullish on the Med-Tech sector heading into 2026 as they expect investor interest given smid-cap valuations continue to remain depressed, while M&A has picked up and the IPO market has opened in some respects. They also highlight how AI is changing our space, enabling improved patient outcomes, increased procedure volumes, more efficiency at the corporate level, and improved surgical accuracy/reproducibility, which they believe could drive some of the greatest changes in healthcare at a time when the system is capacity constrained and in desperate need of solutions.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INMD
Unlock Now

People Also Watch